华美浩联签约中国医学科学院血液病医院

Group 1 - The core viewpoint of the collaboration between Huamei Haolian and the Chinese Academy of Medical Sciences Blood Disease Hospital is to focus on mutual benefits and joint development, addressing challenges in the diagnosis and treatment of complex blood diseases through innovative cooperation in various fields such as medical services, telemedicine, and academic exchanges [1][5][7] - The Chinese Academy of Medical Sciences Blood Disease Hospital is the only tertiary specialized hospital for blood diseases in China, established in 1957, and is recognized as the largest national research-oriented medical institution for blood diseases, with over 300,000 annual patient visits and a leading expert team [3][4] - Huamei Haolian has extensive experience in medical technology services, integrating advanced digital technology platforms and global medical resources, serving over 40 million end-users through customized AI health management solutions [4][5] Group 2 - The collaboration will create a dedicated channel for Huamei Haolian's commercial insurance clients, covering the entire process from outpatient to inpatient services, significantly reducing waiting times for patients and enhancing access to quality medical resources [5][6] - A highlight of the partnership is the establishment of a remote medical consultation platform that connects domestic and international experts, allowing patients with complex conditions to receive tailored treatment plans without the need for long-distance travel [5][6] - An academic exchange platform will be developed to facilitate the transformation of academic achievements and the iteration of diagnostic technologies, supporting talent cultivation and research breakthroughs in the field of hematology [6][7] Group 3 - The strategic cooperation is based on a framework agreement aimed at meeting patient needs and establishing a foundation for long-term collaboration, with plans to continuously expand the depth and breadth of cooperation [7] - The partnership signifies an important step for Huamei Haolian in optimizing medical resource allocation and innovating service models, contributing to the construction of a blood disease diagnosis and treatment ecosystem under the "Healthy China" strategy [7]